



The rise of Sodium-glucose cotransporter 2 inhibitors in the management of



Sign in



All

Images

Videos

翻译成中文

关闭取词

Make Bing your search engine >

27,200 Results

Any time ▾

Effect of sodium glucose cotransporter 2 inhibitor on ...

<https://onlinelibrary.wiley.com/doi/abs/10.1111/hepr.12834>

Sodium glucose cotransporter 2 inhibitor (SGLT2I) was developed for the **treatment** of adults with type **2 diabetes mellitus** (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM.

Cited by: 15

Author: Yuya Seko, Yoshio Sumida, Saiyu Tanak...

Publish Year: 2017

Effects of a sodium-glucose cotransporter 2 inhibitor in ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1019>

A prospective study based on serial liver biopsies was performed to investigate the efficacy of sodium-glucose cotransporter 2 inhibitor for nonalcoholic fatty liver disease complicated with type 2 diabetes mellitus. Conclusion: Treatment for 24 weeks resulted in improvement in histopathologic features in all 5 patients.

Cited by: 16

Author: Norio Akuta, Chizuru Watanabe, Yusuke ...

Publish Year: 2017

[PDF] The Sodium-Glucose Cotransporter 2 Inhibitor ...

<https://www.mdpi.com/1422-0067/19/1/137/pdf>

nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), obesity is highly associated with advanced fibrosis [6]. Type 2 DM is the most common form of diabetes and accounts for 90–95% of all diabetes cases. It continues to be the leading cause of renal disease in the U.S. and around the world [7,8].

Cited by: 5

Author: Dong Wang, Yuhuan Luo, Xiaoxin Wang,...

Publish Year: 2018

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 47665

Manuscript Type: REVIEW

Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

Dokmak A *et al.* SGLT2 inhibitors in NAFLD

Amr Dokmak, Mohammad Almeqdadi, Hirsh Trivedi, Sandeep Krishnan

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the Western world. It is more prevalent in male gender, and with increasing age, obesity, and insulin resistance. Besides weight loss, there are limited treatment

Match Overview

1	Internet 44 words crawled on 11-Oct-2015 worldwidescience.org	1%
2	Internet 25 words crawled on 20-Apr-2019 www.xiahepublishing.com	1%
3	Internet 20 words crawled on 28-Jun-2016 www.wjgnet.com	1%
4	Internet 18 words crawled on 02-Sep-2013 www.medigraphic.com	1%
5	Internet 11 words crawled on 28-Mar-2019 onlinelibrary.wiley.com	<1%
6	Internet 11 words crawled on 14-Jun-2019 aasidpubs.onlinelibrary.wiley.com	<1%
7	Internet 10 words crawled on 17-Feb-2019 www.sleepclinic.be	<1%

All Images Videos

28,300 Results Any time

Effects of a sodium-glucose cotransporter 2 inhibitor in ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1019>

A prospective study based on serial **liver** biopsies was performed to investigate the efficacy of **sodium-glucose cotransporter 2 inhibitor** for **nonalcoholic fatty liver disease** complicated with type 2 diabetes mellitus. Conclusion: Treatment for 24 weeks resulted in improvement in histopathologic features in all 5 patients.

Cited by: 18 Author: Norio Akuta, Chizuru Watanabe, Yusuke ...

Publish Year: 2017

Effect of sodium glucose cotransporter 2 inhibitor on ...

<https://onlinelibrary.wiley.com/doi/abs/10.1111/hepr.12834>

No pharmacological therapies have been established for non-alcoholic **fatty liver disease** (NAFLD). **Sodium glucose cotransporter 2 inhibitor** (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM.

Cited by: 17 Author: Yuya Seko, Yoshio Sumida, Saiyu Tanak...

Publish Year: 2017

Effect of sodium-glucose cotransporter type 2 inhibitors ...

atm.amegroups.com/article/view/22036/html

Effect of **sodium-glucose cotransporter type 2 inhibitors** on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Non-alcoholic **fatty liver disease** (NAFLD) is a common finding in obese people, especially patients with type 2 diabetes (T2DM).

Cited by: 1 Author: André J. Scheen

Publish Year: 2018

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin ...

https://www.researchgate.net/publication/322240536_The_Sodium-Glucose_Cotransporter_2...

PDF | Obesity and obesity related kidney and **liver disease** have become more prevalent over the past few decades, especially in the western world. **Sodium-glucose cotransporter 2** (SGLT2) **inhibitors** ...

Abstract 263: Effects of the sodium glucose cotransporter ...

https://www.researchgate.net/publication/327086680_Abstract_263_Effects_of_the_sodium...

Anti-diabetic agents **sodium glucose cotransporter** (SGLT)-2 **inhibitors** are expected to ameliorate the abnormalities associated with metabolic syndrome including non-alcoholic **fatty liver disease** ...



All

Images

Videos

翻译成中文

开启取词

29,000 Results

Any time ▾

Effects of a sodium-glucose cotransporter 2 inhibitor in ...

<https://aasidpubs.onlinelibrary.wiley.com/doi/10.1002/hep4.1019>

Feb 27, 2017 · A prospective study based on serial **liver** biopsies was performed to investigate the efficacy of **sodium-glucose cotransporter 2 inhibitor** for **nonalcoholic fatty liver disease** complicated with type 2 diabetes mellitus. Conclusion: Treatment for 24 weeks resulted in improvement in histopathologic features in all 5 patients.

Cited by: 18

Author: Norio Akuta, Chizuru Watanabe, Yusuke ...

Publish Year: 2017

Effect of sodium glucose cotransporter 2 inhibitor on ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/hepr.12834>

No pharmacological therapies have been established for non-alcoholic **fatty liver disease** (NAFLD). **Sodium glucose cotransporter 2 inhibitor** (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM.

Cited by: 17

Author: Yuya Seko, Yoshio Sumida, Saiyu Tanaka...

Publish Year: 2017

Inhibition of sodium glucose cotransporter 2 (SGLT2 ...

<https://febs.onlinelibrary.wiley.com/doi/full/10.1002/2211-5463.12598>

Jan 28, 2019 · The **rise** in the incidence of **nonalcoholic** steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of **sodium glucose cotransporter 2** (SGLT2) **inhibitors**, has been tested for its therapeutic effect on NASH; however, no studies to date have demonstrated the preventive effect of an SGLT2 **inhibitor** ...

Author: Ryo Goto, Kenya Kamimura, Yoko Shi... **Publish Year:** 2019

Effect of sodium-glucose cotransporter type 2 inhibitors ...

atm.amegroups.com/article/view/22036/html ▾

Effect of **sodium-glucose cotransporter** type 2 **inhibitors** on **liver** fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Non-alcoholic **fatty liver disease** (NAFLD) is a common finding in obese people, especially patients with type 2 diabetes (T2DM).

Cited by: 1

Author: André J. Scheen

Publish Year: 2018